Close Menu

NCI

The firm will use the contract to further develop its technology capable of matching cancer patients to trials based on molecular and clinical information.

The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.

NCI researchers performed a multi-platform study to elucidate the factors that can contribute to a patient's better-than-expected response to a drug.

The company will discuss with the FDA the possibility of using these preliminary Phase I results as part of its registrational package for the agent.

Researchers surveyed 171 physicians in the NCI-MATCH study to determine their tumor profiling practices and barriers to participation in future studies.

The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.

The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.

However, the lack of biomarker-specific treatment data kept researchers from definitively concluding that precision oncology treatments were behind an accelerated rate of NSCLC mortality decline.

The firm's investigational immunotherapy PRGN-2009 will be evaluated in patients as a monotherapy and in combination with an investigational bifunctional fusion protein.

A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.

Pages